Cas:34698-41-4 1-Indanamine manufacturer & supplier

Chemical Name:1-Indanamine

CAS.NO:34698-41-4

Synonyms:1-Aminoindan;INDAN-1-YLAMINE;2,3-dihydro-1H-inden-1-amine;Indan-1-amine;EINECS 252-158-7;(n)-1-aminoindan;1-Aminoinden;1-Aminoindane;1,3-dihydro-1H-inden-1-amine;1-indanylamine;indane amine;1H-Inden-1-amine, 2,3-dihydro-, (±)-;MFCD00003799;1-Iminoindane;1H-Inden-1-amine, 2,3-dihydro-;1-Indanamine;RS-(2,3-dihydro-1H-inden-1-yl)-amine;1-AMINOHYDRINDENE

Molecular Formula:C₉H₁₁N

Molecular Weight:133.190

HS Code:29214980

Physical and Chemical Properties:

Melting point:15 °C(lit.)

Boiling point:225.0±19.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.580

PSA:26.02000

Exact Mass:133.089142

LogP:1.61

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like 1-Aminoindan chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-AMINOHYDRINDENE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3-dihydro-1H-inden-1-amine Use and application,(n)-1-aminoindan technical grade,usp/ep/jp grade.

Related News: The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. 1-Indanamine manufacturer A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018. 1-Indanamine supplier APIs are generally manufactured through a variety of processes that include. 1-Indanamine vendor The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. 1-Indanamine factory Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).